Biocept

About Biocept

Biocept is a biotechnology company specializing in the development of innovative diagnostic solutions, primarily focusing on liquid biopsy tests for cancer detection and monitoring. The company serves a diverse range of clients including medical and surgical oncologists, pathologists, hospitals, cancer centers, universities, and pharmaceutical and clinical researchers. Operating in the healthcare and biotechnology markets, Biocept's business model revolves around providing advanced diagnostic services that utilize a patented methodology to isolate cancer material from blood samples, such as circulating tumor cells (CTCs) and cell-free circulating tumor DNA (ctDNA). This approach offers a non-invasive alternative to traditional tissue biopsies, particularly beneficial for patients where tissue biopsies are insufficient or not possible. Additionally, Biocept has expanded its services to include COVID-19 testing, supporting public health efforts during the pandemic. The company generates revenue through the sale of its diagnostic tests and services, partnering with industry leaders and major cancer centers to continually enhance its offerings.